Guidance

Advice to the Competition and Markets Authority (CMA) on the relevant customer benefits of an anticipated pathology joint venture in south east England

The advice relates to the anticipated pathology joint venture between Basildon and Thurrock University Hospital NHS Foundation Trust, Southend University Hopsital NHS Foundation Trust and Integrated Pathology Partnerships Limited.

• From: Monitor
• Published: 29 August 2014

Applies to England

Documents

Anticipated pathology joint venture between Basildon and Thurrock University Hospitals NHS Foundation Trust, Southend University Hospital NHS Foundation Trust and Integrated Pathology Partnership Limited

PDF, 76.8 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

You can find out more about the CMA’s investigation here.

Published 29 August 2014